DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1002 Davies NM, Anderson KE. Clinical pharmacokinetics of
naproxen. Clin Pharmacokinet, 1997b, 32:268–293.
Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical
pharmacokinetics and pharmacodynamics of celecoxib: a
selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet,
2000, 38:225–242.
Davies NM, Skjodt NM. Clinical pharmacokinetics of
meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal
anti-inflammatory drug. Clin Pharmacokinet, 1999, 36:
115–126.
Davies NM, Teng XW, Skjodt NM. Pharmacokinetics of rofecoxib:
A specific cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet,
2003, 42:545–556.
Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics
and pharmacodynamics of allopurinol and oxypurinol. Clin
Pharmacokinet, 2007, 46:623–644.
Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and
upper gastrointestinal safety of celecoxib for treatment of
osteoarthritis and rheumatoid arthritis: Systematic review of
randomised controlled trials. BMJ, 2002, 325:619.
Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors
and pathways activated by TNF superfamily. Cytokine
Growth Factor Rev, 2003, 14:193–209.
Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet
agents for preventing pre-eclampsia and its complications.
Cochrane Database Syst Rev, 2004, (1):CD004659.
Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin
confers atheroprotection on female mice. Science, 2004,
306:1954–1957.
Engblom D, Saha S, Engström L, et al. Microsomal
prostaglandin E synthase-1 is the central switch during
immune-induced pyresis. Nat Neurosci, 2003, 6:1137–1138.
Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification
of a renal urate anion exchanger that regulates blood
urate levels. Nature, 2002, 417:447–452.
Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of
lumiracoxib with naproxen and ibuprofen in the Therapeutic
Arthritis Research and Gastrointestinal Event Trial (TAR-
GET), cardiovascular outcomes: Randomised controlled trial.
Lancet, 2004, 364:675–684.
FitzGerald GA, Patrono C. The coxibs, selective inhibitors of
cyclooxygenase-2. N Engl J Med, 2001, 345:433–442.
Fleischmann R, Iqbal I, Slobodin G. Meloxicam. Expert Opin
Pharmacother, 2002, 3:1501–1512.
Fries S, Grosser T, Price TS, et al. Marked interindividual variability
in the response to selective inhibitors of cyclooxygenase-2.
Gastroenterology, 2006, 130:55–64.
Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious
gastrointestinal complications related to use of nonsteroidal
anti-inflammatory drugs. A meta-analysis. Ann Intern Med,
1991, 115:787–796.
García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal
complications among users of traditional NSAIDs
and COXIBs in the general population. Gastroenterology,
2007, 132:498–506.
García Rodríguez LA, Varas-Lorenzo C, Maguire A, González-
Pérez A. Nonsteroidal antiinflammatory drugs and the risk of
myocardial infarction in the general population. Circulation,
2004, 109:3000–3006.
Glasgow JF, Middleton B. Reye syndrome—Insights on causation
and prognosis. Arch Dis Child, 2001, 85:351–353.
SECTION IV
INFLAMMATION, IMMUNOMODULATION, AND HEMATOPOIESIS
Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular
consequences of COX-2 inhibition: therapeutic
challenges and opportunities. J Clin Invest, 2006, 116:4–15.
Guay-Woodford LM. Bartter syndrome: Unraveling the pathophysiologic
enigma. Am J Med, 1998, 105:151–161.
Guttadauria M. The clinical pharmacology of piroxicam. Acta
Obstet Gynecol Scand Suppl, 1986, 138:11–13.
Haanen C. Sulindac and its derivatives: A novel class of anticancer
agents. Curr Opin Investig Drugs, 2001, 2:677–683.
Hallak A, Alon-Baron L, Shamir R, et al. Rofecoxib reduces
polyp recurrence in familial polyposis. Dig Dis Sci, 2003,
48:1998–2002.
Harris RE, Beebe-Donk J, Doss H, Burr Doss D, et al. Aspirin,
ibuprofen, and other non-steroidal anti-inflammatory drugs in
cancer prevention: A critical review of non-selective COX-2
blockade (review). Oncol Rep, 2005, 13:559–583.
Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl
J Med, 2008, 359:285–292.
Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis
by nonsteroidal anti-inflammatory drugs: Insight into
mechanisms and implications for cancer growth and ulcer
healing. Nat Med, 1999, 5:1418–1423.
Jungnickel PW, Maloley PA, Vander Tuin EL, et al. Effect of two
aspirin pretreatment regimens on niacin-induced cutaneous
reactions. J Gen Intern Med, 1997, 12:591–596.
Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors
superior to traditional non steroidal anti-inflammatory drugs?
BMJ, 2002, 324:1287–1288.
Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane
A(2) and prostacyclin in the development of atherosclerosis
in apoE-deficient mice. J Clin Invest, 2004, 114:784–794.
Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of highdose
ibuprofen in patients with cystic fibrosis. N Engl J Med,
1995, 332:848–854.
Kulling PE, Backman EA, Skagius AS, Beckman EA. Renal
impairment after acute diclofenac, naproxen, and sulindac
overdoses. J Toxicol Clin Toxicol, 1995, 33:173–177.
Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic
illnesses, operations and medications: Case control results
from the Melbourne Colorectal Cancer Study. 1988. Int J
Epidemiol, 2007, 36:951–957.
Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis
for selective inhibition of cyclooxygenase-2 by antiinflammatory
agents. Nature, 1996, 384:644–648.
Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal
safety of etoricoxib and diclofenac in patients with
osteoarthritis and rheumatoid arthritis in the Multinational
Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme:
A randomised comparison. Lancet, 2007, 369:465–473.
Langenbach R, Loftin CD, Lee C, Tiano H. Cyclooxygenasedeficient
mice. A summary of their characteristics and susceptibilities
to inflammation and carcinogenesis. Ann N Y Acad
Sci, 1999, 889:52–61.
Levy M, Spino M, Read SE. Colchicine: A state-of-the-art
review. Pharmacotherapy, 1991, 11:196–211.
Loftin CD, Trivedi DB, Langenbach R. Cyclooxygenase-1-
selective inhibition prolongs gestation in mice without adverse
effects on the ductus arteriosus. J Clin Invest, 2002, 110:
549–557.
Lopshire JC, Nicol GD. The cAMP transduction cascade mediates
the prostaglandin E2 enhancement of the capsaicin-elicited